î
îŒ
î
MoonLake Immunotherapeutics
MLTX13.830USD
-0.040-0.29%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
881.03Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± MoonLake Immunotherapeutics äŒæ¥å
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeuticsã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãMLTX
äŒç€ŸåMoonLake Immunotherapeutics
äžå Žæ¥Oct 20, 2020
æé«çµå¶è²¬ä»»è
ãCEOãSantos Da Silva (Jorge)
åŸæ¥å¡æ°100
蚌åžçš®é¡Ordinary Share
決ç®ææ«Oct 20
æ¬ç€Ÿæåšå°Dorfstrasse 29
éœåžZUG
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœSwitzerland
éµäŸ¿çªå·6300
é»è©±çªå·41415108022
ãŠã§ããµã€ãhttps://moonlaketx.com/
äŒæ¥ã³ãŒãMLTX
äžå Žæ¥Oct 20, 2020
æé«çµå¶è²¬ä»»è
ãCEOãSantos Da Silva (Jorge)
MoonLake Immunotherapeuticsã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Mon, Dec 1
æŽæ°æå»: Mon, Dec 1
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
ä»ã®
54.61%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
ä»ã®
54.61%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
47.09%
Individual Investor
9.25%
Investment Advisor
6.20%
Investment Advisor/Hedge Fund
5.92%
Research Firm
1.10%
Venture Capital
0.49%
Bank and Trust
0.10%
Pension Fund
0.04%
ä»ã®
29.81%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Bodenstedt (Matthias)
616.67K
0.97%
--
--
Mar 15, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Tue, Dec 2
æŽæ°æå»: Tue, Dec 2
éæå
æ¯ç
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
詳现ãèŠã
ALPS Medical Breakthroughs ETF
æ¯ç0.27%
Global X Guru Index ETF
æ¯ç0.22%
Virtus LifeSci Biotech Clinical Trials ETF
æ¯ç0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
æ¯ç0.02%
Strive Small-Cap ETF
æ¯ç0.02%
Nuveen ESG Small-Cap ETF
æ¯ç0.02%
iShares Morningstar Small-Cap ETF
æ¯ç0.01%
John Hancock Multifactor Small Cap ETF
æ¯ç0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
æ¯ç0.01%
Fidelity Nasdaq Composite Index ETF
æ¯ç0.01%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
MoonLake Immunotherapeuticsã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îMoonLake Immunotherapeuticsã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
BVF Partners L.P.ã¯19.75Mæ ªãä¿æããŠãããããã¯å šäœã®31.10%ã«çžåœããŸãã
Santos da Silva (Jorge)ã¯3.08Mæ ªãä¿æããŠãããããã¯å šäœã®4.85%ã«çžåœããŸãã
Reich (Kristian)ã¯3.13Mæ ªãä¿æããŠãããããã¯å šäœã®4.93%ã«çžåœããŸãã
Avoro Capital Advisors LLCã¯4.15Mæ ªãä¿æããŠãããããã¯å šäœã®6.54%ã«çžåœããŸãã
Cormorant Asset Management, LPã¯1.99Mæ ªãä¿æããŠãããããã¯å šäœã®3.14%ã«çžåœããŸãã
BVF Partners L.P.ã¯19.75Mæ ªãä¿æããŠãããããã¯å šäœã®31.10%ã«çžåœããŸãã
Santos da Silva (Jorge)ã¯3.08Mæ ªãä¿æããŠãããããã¯å šäœã®4.85%ã«çžåœããŸãã
Reich (Kristian)ã¯3.13Mæ ªãä¿æããŠãããããã¯å šäœã®4.93%ã«çžåœããŸãã
Avoro Capital Advisors LLCã¯4.15Mæ ªãä¿æããŠãããããã¯å šäœã®6.54%ã«çžåœããŸãã
Cormorant Asset Management, LPã¯1.99Mæ ªãä¿æããŠãããããã¯å šäœã®3.14%ã«çžåœããŸãã
MoonLake Immunotherapeuticsã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îMoonLake Immunotherapeuticsã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
MoonLake ImmunotherapeuticsïŒMLTXïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãMoonLake Immunotherapeuticsã®æ ªåŒãä¿æããŠããæ©é¢ã¯336瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ52.26Mã§ãå
šäœã®73.22%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-38.84%å¢å ããŠããŸãã
MoonLake Immunotherapeuticsã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãMoonLake Immunotherapeuticsã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
